Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 4. Dabrafenib and trametinib changed the cellular components of the tumor microenvironment. Dabrafenib and trametinib changed the cellular components.

Published bySiska Atmadjaja Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 4. Dabrafenib and trametinib changed the cellular components of the tumor microenvironment. Dabrafenib and trametinib changed the cellular components."— Presentation transcript:

1 Fig. 4. Dabrafenib and trametinib changed the cellular components of the tumor microenvironment.
Dabrafenib and trametinib changed the cellular components of the tumor microenvironment. On day 5 after ACT, spleens and tumors were isolated and stained with fluorescent-labeled antibodies and then analyzed by FACS, with three mice in each group (mean ± SD). (A) MO-MDSC (CD11b+Ly6CHiLy6GLo) presented as percentage of CD11b+ cells. *P = 0.06, pmel D versus pmel V in spleen; P = 0.009, pmel V versus mock V in tumor (unpaired t test, n = 3). (B) PMN-MDSC (CD11b+Ly6CLowLy6GHi) presented as percentage of CD11b+ cells. *P = 0.002, mock D + T versus mock V in tumor (unpaired t test, n = 3). (C) Analysis of macrophages (F4/80+CD11b+). *P = 0.04, pmel D versus pmel V; P = 0.002, pmel D + T versus pmel V, both in tumors (unpaired t test, n = 3). (D) Analysis of Tregs (CD4+CD25+FOXp3+). *P = 0.002, pmel D versus pmel V in tumors (unpaired t test, n = 3). (E) Gating strategy and representative FACS plots in tumors. Siwen Hu-Lieskovan et al., Sci Transl Med 2015;7:279ra41 Published by AAAS

Download ppt "Fig. 4. Dabrafenib and trametinib changed the cellular components of the tumor microenvironment. Dabrafenib and trametinib changed the cellular components."

Similar presentations

S2 Fig. Phenotype of donor cells in the spleen and bone marrow of male mice. Splenocytes and bone marrow were isolated from male donor mice and stained.

S2 Fig. Phenotype of donor cells in the spleen and bone marrow of male mice. Splenocytes and bone marrow were isolated from male donor mice and stained.
Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Pitx2 haploinsufficiency rescues Tbx5 haploinsufficiency in mice

Pitx2 haploinsufficiency rescues Tbx5 haploinsufficiency in mice
Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.

Fig. 2. LUM015 fluorescently labels tumor cells in mouse models of STS and breast cancer. LUM015 fluorescently labels tumor cells in mouse models of STS.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 5 Maraba induces antitumor T cell immunity.

Fig. 5 Maraba induces antitumor T cell immunity.
Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.
Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.

Fig. 6. Increased efficacy of immunotherapy in lymphangiogenic B16 melanomas depends on CCR7 signaling before therapy and local activation and expansion.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade

Maraba treatment sensitizes 4T1 tumors to immune checkpoint blockade
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.
Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.
Expression of CD36 and psap in a TMA of human ovarian cancer patients

Expression of CD36 and psap in a TMA of human ovarian cancer patients
Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 5 A competent Fc is required for the antitumor immune response.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.
Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.
Fig. 3. Tumor hypoxia and acidosis promote immunosuppression.

Fig. 3. Tumor hypoxia and acidosis promote immunosuppression.

Similar presentations

Ads by Google